People · Operator
Named in public records as an officer, director or promoter · active 2017–2023 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Genapsys, Inc. | — | Biotechnology | Series B | $106.0M | $871.9M | 2017 |
| RareCyte, Inc. | — | Other | Series B | $79.8M | $103.7M | 2017 |
| JumpCode Genomics, Inc. | — | Biotechnology | Series B | $38.7M | $23.4M | 2020 |
Frank Witney at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Frank Witney on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Liang | 1 | 9 |
| Eugene Chen | 1 | 9 |
| Keith Brown | 1 | 8 |
| Andrew J. Schwab | 1 | 7 |
| Court Turner | 1 | 6 |
| Brian Daniels | 1 | 5 |
| Robert Zollars | 1 | 5 |
| Jason Myers | 1 | 4 |
| Dan Kidle | 1 | 4 |
| Kevin Li | 1 | 4 |
| Robert Shepler | 1 | 4 |
| Frank J. Witney | 1 | 2 |
| Fred F. Nazem | 1 | 2 |
| Joseph Victor | 1 | 2 |
| Joel Rotroff | 1 | 2 |
| Robert J. Weisskoff | 1 | 2 |
| Kirk Malloy | 1 | 2 |
| Brandon Poe | 1 | 2 |
| Evan Castiglia | 1 | 1 |
| Harish Soundararajanand | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.